Indian pharma to revive by Apr; see better margins: Cadila

Pankaj Patel, Chairman & MD, Zydus CadilaNo sector has been as badly hit by regulators’ punitive measures as the Indian pharma.

The year gone by saw numerous USFDA import alerts, red flags, etc on various pharma majors that led to their stocks being hammered significantly. However, the increased inspection is a positive for the industry, opines Pankaj R Patel, chairman and managing director, Zydus Cadila Healthcare . This, despite the fact that the company has received a warning letter from the US regulator.

Read more



Tagged as: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Categorised in: Interviews, Pharma & Healthcare, Sector News

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: